Skip to search formSkip to main contentSkip to account menu

otamixaban

Known as: 2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester, 2-(R)-(3-carbamimidoylbenzyl)-3-(R)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Otamixaban has a short half-life of 1.5 to 3… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Cyclic N-OxidesFactor Xa inhibitorsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
New anticoagulants and the future of cardiology.
2009
2009
Resumen de los ensayos clínicos presentados en las sesiones científicas del Congreso de la Sociedad Europea de Cardiología (Barcelona, España, 29 de agosto-2 de septiembre de 2009)
Review
2007
Review
2007
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Factor Xa (fXa) is a critical serine protease situated at the confluence of the intrinsic and extrinsic pathways of the blood… 
2006
2006
Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure
The pharmacokinetics of otamixaban was investigated in healthy male subjects over a wide range of intravenous doses, with… 
2006
2006
Asymmetric synthesis of intermediates for otamixaban and premafloxacin by the chiral ligand-controlled asymmetric conjugate addition of a lithium amide.
A chiral ligand-controlled conjugate addition reaction of lithium benzyl(trimethylsilyl)amide with tert-butyl enoates gave the… 
2006
2006
Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease
2005
2005
Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor
Summary This manuscript reports the assessment of pharmacodynamic (PD) markers of anti-coagulation in the first-in-man study with… 
2005
2005
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers
Anticoagulant andanti-platelet effectsare maintained following coadministration of otamixaban, adirect factor Xa inhibitor, with… 
2004
2004
Diastereoselective alkylation of beta-amino esters: structural and rate studies reveal alkylations of hexameric lithium enolates.
Alkylation of beta-amino ester enolates proceeds with high diastereoselectivity. Single crystal, powder, and solution X-ray… 
1994
1994
Modern Drug Synthesis
Preface. Contributors. I. Infectious Diseases. Chapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)